Why chronic gut inflammation can turn into colon cancer
Researchers have identified a potential key mechanism explaining the elevated risk of colorectal cancer faced by individuals with inflammatory bowel disease (IBD). The findings, stemming from preclinical research, reveal a chain reaction within the immune system where gut signals can prompt a surge of white blood cells, ultimately fostering an environment conducive to tumor growth. This work also suggests new avenues for detecting, monitoring, and potentially mitigating cancer risk in those living with IBD.
Unraveling the Connection Between IBD and Cancer
The Role of TL1A
The research focused on TL1A, an inflammatory signaling protein already known to be associated with both IBD and colorectal cancer. While drugs blocking TL1A have demonstrated promise in clinical trials for IBD, the precise way this protein contributes to inflammation and cancer development remained unclear. A study published in Immunity showed that TL1A significantly influences the gut through a specific group of immune cells called ILC3s.
How the Immune System Reacts
When TL1A activates ILC3 cells, they trigger the release of large numbers of neutrophils – a type of white blood cell – from the bone marrow. This influx of neutrophils isn’t simply a matter of increased cell count; the researchers found that ILC3s also alter the behavior of these neutrophils in ways that actively promote tumor formation. “These findings are important given the intense interest in the medical community to understand TL1A’s role in IBD and its potential role in associated colorectal cancers — for which we have had few strategies to mitigate the cancer risk,” explained Dr. Randy Longman, director of the Jill Roberts Center for Inflammatory Bowel Disease at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center and an associate professor of medicine at Weill Cornell Medicine.
Why IBD Increases Cancer Risk
IBD, encompassing Crohn’s disease and ulcerative colitis, is characterized by persistent inflammation of the digestive tract. This chronic inflammation doesn’t just cause digestive discomfort; it also increases the risk of other autoimmune and inflammatory conditions and, critically, significantly elevates the risk of colorectal cancer. Colorectal cancer developing in individuals with IBD often presents at younger ages and is associated with less favorable outcomes.
The GM-CSF Connection
The researchers discovered that TL1A’s impact on tumor growth is largely mediated through its effects on ILC3 cells. Activated ILC3 cells release granulocyte-macrophage colony-stimulating factor (GM-CSF), a substance that stimulates blood cell production. This initiates a process called “emergency granulopoiesis” – a rapid increase in neutrophil production within the bone marrow – followed by the migration of these cells to the gut. Experiments using mouse models of intestinal cancer demonstrated that the presence of these neutrophils alone was sufficient to accelerate tumor development.
Changes Within Immune Cells
Neutrophils are already known to contribute to colorectal tumor growth by releasing reactive molecules that can damage DNA in the gut lining. This study further revealed that ILC3 cells trigger a specific pattern of gene activity within neutrophils. This pattern involves increased activity of genes linked to both the initiation and progression of cancer. Similar changes in gene expression were observed in colon tissue samples taken from individuals with IBD-related colitis. Notably, this tumor-promoting genetic signature was less pronounced in patients who had received an experimental treatment blocking TL1A.
Looking Ahead
The findings suggest that multiple components of this immune pathway could become targets for future treatments and preventative strategies. Beyond TL1A itself, ILC3 cells, GM-CSF, and the neutrophils recruited by ILC3s may all play a role in developing therapies aimed at treating IBD while simultaneously reducing the risk of colorectal cancer. Dr. Sílvia Pires, an instructor in medicine and member of the Longman Laboratory, stated, “I think it will be exciting for clinicians in the IBD field to know that there is a systemic process at work here, involving both the gut and the bone marrow, with the potential to drive precision medicine in IBD.”
Researchers are continuing to investigate the intricacies of this immune communication network during gut inflammation. Future studies will explore whether early or intermittent exposure to GM-CSF could potentially prime bone marrow cells, increasing susceptibility to IBD over time. This could pave the way for earlier interventions and preventative measures.
Frequently Asked Questions
What is TL1A?
TL1A is an inflammatory signaling protein linked to both inflammatory bowel disease (IBD) and colorectal cancer.
What are ILC3 cells?
ILC3 cells are a group of immune cells found in the gut that, when activated by TL1A, trigger a surge of neutrophils from the bone marrow.
What is GM-CSF?
GM-CSF is a substance released by ILC3 cells that stimulates blood cell production, leading to “emergency granulopoiesis” – a rapid increase in neutrophil production.
Given these new insights into the complex interplay between the immune system, gut inflammation, and cancer development, what further research do you believe is most crucial for improving outcomes for individuals with IBD?